Rheumatology and Therapy (Mar 2023)

Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

  • Hua Ye,
  • Shengyun Liu,
  • Jian Xu,
  • Kexia Chai,
  • Dongyi He,
  • Yongfei Fang,
  • Qibing Xie,
  • Huaxiang Liu,
  • Ying Liu,
  • Bingzhu Hua,
  • Jiankang Hu,
  • Zhiyi Zhang,
  • Mingxuan Zhou,
  • Dongbao Zhao,
  • Yan Li,
  • Zhenyu Jiang,
  • Meimei Wang,
  • Jingyang Li,
  • Zhuoli Zhang,
  • Xiaomei Li,
  • Yang Li,
  • Erwei Sun,
  • Liqi Bi,
  • Wei Wei,
  • Ning Tie,
  • Lan He,
  • Xiangyang Huang,
  • Yan Zhang,
  • Qingchun Huang,
  • Xiaofei Wang,
  • Xiangyuan Liu,
  • Jing Li,
  • Yin Su

DOI
https://doi.org/10.1007/s40744-023-00544-2
Journal volume & issue
Vol. 10, no. 3
pp. 757 – 773

Abstract

Read online

Abstract Objectives The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. Methods We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with a stable dose of methotrexate. Patients were enrolled randomly with a ratio of 1:1 to receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30. The primary efficacy endpoint was American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 30. The non-inferiority was established if the lower limit of the one-sided 97.5% confidence interval (CI) for the difference was more than − 15% and the equivalence was established if the two-sided 95% CI was within ± 15% in an exploratory equivalence analysis. The secondary endpoints included other efficacy assessment parameters, as well as immunogenicity, safety, and pharmacokinetics. Results In the full analysis population (FAS), 110 (57.6%) of 191 patients in the CMAB008 group and 120 (62.2%) of 193 patients in the innovator infliximab group reached the primary outcome of ACR20 at week 30. The differences of the rates were − 4.6% and the lower limit of one-sided 97.5% confidence interval was − 14.29%, not less than the lower limit of the non-inferiority margin (− 15%); so CMAB008 was non-inferior to innovator infliximab. Further, CMAB008 was equivalent to innovator infliximab both in FAS (difference − 4.6%, 95% CI − 14.29% to 5.12%) and PPS (difference – 3.3%, 95% CI – 13.18% to 6.62%). The efficacy, safety, immunogenicity, and pharmacokinetics are highly similar between CMAB008 and innovator infliximab. Conclusions Non-inferior efficacy of CMAB008 to innovator infliximab is illustrated with similar early and lasting therapeutic effects, and the equivalence is further demonstrated. CMAB008 is well tolerated and has semblable safety compared with the innovator infliximab. Trial registration number NCT03478111.

Keywords